Novel pyridine-containing azacrownethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution-Reference-Cited by-同舟云学术

Novel pyridine-containing azacrownethers for the chelation of therapeutic bismuth radioisotopes: Complexation study, radiolabeling, serum stability and biodistribution

Published:2018-05 Issue: Volume:60 Page:1-10
ISSN:0969-8051
Container-title:Nuclear Medicine and Biology
language:en
Short-container-title:Nuclear Medicine and Biology

Author:

Egorova B.V.,Matazova E.V.,Mitrofanov A.A.,Aleshin G.Yu.,Trigub A.L.,Zubenko A.D.,Fedorova O.A.,Fedorov Yu.V.,Kalmykov S.N.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Molecular Medicine

Reference37 articles.

1. Targeted alpha therapy with 213 Bi;Morgenstern;Curr Radiopharm,2011

2. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: a pilot trial;Cordier;Eur J Nucl Med Mol Imaging,2010

3. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience;Kratochwil;Eur J Nucl Med Mol Imaging,2014

4. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer;Kratochwil;Semin Nucl Med,2016

5. Targeted alpha particle immunotherapy for myeloid leukemia;Jurcic;Blood,2002

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel candidate theranostic radiopharmaceutical based on strontium hexaferrite nanoparticles conjugated with azacrown ligand;Dalton Transactions;2023

2. Delivery of radiopharmaceuticals and theranostic agents: targeted alpha therapy;Novel Platforms for Drug Delivery Applications;2023

3. CeO2-Azacrown Conjugate as a Nanoplatform for Combined Radiopharmaceuticals;Nanomaterials;2022-12-18

4. Bismuth chelation for targeted alpha therapy: Current state of the art;Nuclear Medicine and Biology;2022-11

5. In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice;International Journal of Pharmaceutics;2022-09